Abstract
Alzheimers disease (AD) is the most common form of dementia in the elderly, and is characterized by the deposition of extracellular amyloid plaques primarily composed of the β-amyloid peptide (Aβ). While these plaques define the pathology of AD, disease progression has been shown to correlate more closely with the level of synaptotoxicity induced by soluble Aβ oligomers. Recent evidence suggests that these oligomers are covalently crosslinked, possibly due to the interaction of Aβ with redox-active metal ions. These findings offer new avenues for the treatment and prevention of disease, by modulating metal binding or preventing the formation of neurotoxic Aβ oligomers. An understanding of the chemical nature of Aβ is also required to elucidate the synaptotoxic process or processes in AD, which have so far resisted explanation.
Keywords: Beta-amyloid, Aβ, oligomer, covalent crosslinks, metal, neurotoxicity, synaptotoxicity
Current Alzheimer Research
Title: Is Covalently Crosslinked Aβ Responsible for Synaptotoxicity in Alzheimers Disease?
Volume: 5 Issue: 6
Author(s): R. Naylor, A. F. Hill and K. J. Barnham
Affiliation:
Keywords: Beta-amyloid, Aβ, oligomer, covalent crosslinks, metal, neurotoxicity, synaptotoxicity
Abstract: Alzheimers disease (AD) is the most common form of dementia in the elderly, and is characterized by the deposition of extracellular amyloid plaques primarily composed of the β-amyloid peptide (Aβ). While these plaques define the pathology of AD, disease progression has been shown to correlate more closely with the level of synaptotoxicity induced by soluble Aβ oligomers. Recent evidence suggests that these oligomers are covalently crosslinked, possibly due to the interaction of Aβ with redox-active metal ions. These findings offer new avenues for the treatment and prevention of disease, by modulating metal binding or preventing the formation of neurotoxic Aβ oligomers. An understanding of the chemical nature of Aβ is also required to elucidate the synaptotoxic process or processes in AD, which have so far resisted explanation.
Export Options
About this article
Cite this article as:
Naylor R., Hill F. A. and Barnham J. K., Is Covalently Crosslinked Aβ Responsible for Synaptotoxicity in Alzheimers Disease?, Current Alzheimer Research 2008; 5 (6) . https://dx.doi.org/10.2174/156720508786898433
DOI https://dx.doi.org/10.2174/156720508786898433 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Computer Simulations of Alzheimers Amyloid β-Protein Folding and Assembly
Current Alzheimer Research The Use of Stem Cells in Regenerative Medicine for Parkinson’s and Huntington’s Diseases
Current Medicinal Chemistry Impact of Natural Dietary Agents on Multiple Myeloma Prevention and Treatment: Molecular Insights and Potential for Clinical Translation
Current Medicinal Chemistry Recent Patents, Regulatory Issues, and Toxicity of Nanoparticles in Neuronal Disorders
Current Drug Metabolism Pathways by Which Aβ Facilitates Tau Pathology
Current Alzheimer Research Impact of Dietary Fats on Brain Functions
Current Neuropharmacology Serotonin 5-HT6 Receptor Antagonists for the Treatment of Alzheimers Disease
Current Topics in Medicinal Chemistry Proteomic Alterations by Mutations Involved in Parkinson's Disease and Related Disorders
Current Protein & Peptide Science Val17Ile Single Nucleotide Polymorphisms Similarly as Ala15Thr Could be Related to the Lower Secretory Dynamics of PAI-1 Secretion – Theoretical Evidence
Current Molecular Medicine Editorial (Thematic Issue: Effective and Promising Treatments for Neurological Disorders and Cancer)
Current Pharmaceutical Design Cognitive Impairment in the Septic Brain
Current Neurovascular Research Role of Inflammatory Markers in Elderly Type 2 Diabetic Patients with Mild Cognitive Impairment
Current Diabetes Reviews Adverse Drug Reactions Related to Drug Administration in Hospitalized Patients
Current Drug Safety Metal and Inflammatory Targets for Alzheimers Disease
Current Drug Targets <i>In silico</i> Screening of Pyridoxine Carbamates for Anti-Alzheimer’s Activities
Central Nervous System Agents in Medicinal Chemistry Cardiovascular Drugs and Bone
Current Drug Safety Treatment of Alzheimer's Disease: Classical Therapeutic Approach
Current Pharmaceutical Analysis Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues
Current Drug Safety Getting Rid of Intracellular Aβ - Loss of Cellular Degradation Leads to Transfer Between Connected Neurons
Current Pharmaceutical Design Cornel Iridoid Glycoside Suppresses Tau Hyperphosphorylation and Aggregation in a Mouse Model of Tauopathy through Increasing Activity of PP2A
Current Alzheimer Research